Skip to main
FBLG
FBLG logo

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics Inc. demonstrates a strong positive outlook due to its strategic partnership with Charles River, which bolsters the company’s manufacturing capabilities and prepares it for an upcoming clinical trial launch. The completion of a successful first-in-human trial for diabetic foot ulcers, coupled with a robust cell bank establishment, positions the company favorably for advancing its pipeline of fibroblast-based therapies. Additionally, the recent $5 million tranche from a $25 million financing agreement enhances FibroBiologics' financial stability, enabling further investments in research and manufacturing to support large-scale production in multiple high-value therapeutic areas.

Bears say

FibroBiologics Inc faces significant challenges as it operates within a highly competitive and uncertain clinical-stage environment, which raises concerns about the commercialization viability of its fibroblast-based therapies. The market for diabetic foot ulcers, despite being a major unmet medical need, has limited long-term treatment options, highlighting the difficulties the company may encounter in effectively addressing this segment. Additionally, the reliance on successful clinical outcomes and regulatory approvals creates inherent risks that could adversely impact financial performance and investor confidence moving forward.

Fibrobiologics Inc (FBLG) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.